Modeling the long-term persistence of hepatitis a antibody after a two-dose vaccination schedule in argentinean children

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages 417-425

  López, Eduardo L ^a   Contrini, María Marta ^a   Mistchenko, Alicia ^a   Kieffer, Alexia ^b   Baggaley, Rebecca F ^c   Di Tanna, Gian Luca ^c   Desai, Kamal ^d   Rasuli, Anvar ^b   Armoni, Judith ^e  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b SANOFI PASTEUR   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d EVIDERA   (United Kingdom)

^e Sanofi Pasteur   (Argentina)

Author keywords

antibody persistence; Argentina; Hepatitis A; inactivated vaccine; pediatric

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARGENTINA; ARGENTINIAN; ARTICLE; CHILD; DECISION MAKING; FEMALE; FOLLOW UP; HEPATITIS A; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; PRIORITY JOURNAL; SEROLOGY; SERUM; VACCINATION; ADULT; BLOOD; COHORT ANALYSIS; HEPATITIS A VIRUS; IMMUNIZATION; IMMUNOLOGY; LONGITUDINAL STUDY; PRESCHOOL CHILD; PROCEDURES; STATISTICAL MODEL; TIME;

ADOLESCENT; ADULT; ARGENTINA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; TIME FACTORS; VACCINATION;

EID: 84937580783     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000605     Document Type: Article

References (46)

1. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653-6657.
2. Purcell R, Emerson S. Natural history and experimental models. In: Thomas H, Lemon S, Zuckerman A, eds. Viral Hepatitis. 3rd ed. Oxford: Blackwell Publishing; 2005; p. 109-125.
3. World Health Organization. Hepatitis A vaccines: WHO position paper. Wkly Epidemiol Rec. 2000;75:38-44.
4. World Health Organization. Position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2012;87(28-29):261-276. Available at:http://www.who.int/ wer/2012/wer8728-29.pdf. Accessed August 13, 2013.
5. Van Herck K, Crasta PD, Messier M, et al. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother. 2012;8:323-327.
6. Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis. 2013;17:e939-e944.
7. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-Term antibody persistence. J Med Virol. 1994;44:446-451.
8. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol. 1996;49:235-241.
9. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-Term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol. 2000;60:1-7.
10. Cheuvart B, Burgess M, Zepp F, et al. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine. 2004;23:336-342.
11. Tiru M, Hallander HO, Gustafsson L, et al. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine. 2000;18:2295-2306.
12. Renard D, Bruckers L, Molenberghs G, et al. Repeated-measures models to evaluate a hepatitis B vaccination programme. Stat Med. 2001;20:951-963.
13. Thiesen B, Greenwood B, Brieske N, et al. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein. Vaccine. 1997;15:209-219.
14. Bailleux F, Coudeville L, Kolenc-Saban A, et al. Predicted long-Term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine. 2008;26:3903-3908.
15. Desai K, Coudeville L, Bailleux F. Modelling the long-Term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30:2510-2515.
16. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-Term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324-4333.
17. Tapia-Conyer R, Santos JI, Cavalcanti AM, et al. Hepatitis A in Latin America: A changing epidemiologic pattern. Am J Trop Med Hyg. 1999;61:825-829.
18. Teunis PF, van der Heijden OG, de Melker HE, et al. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect. 2002;129:479-489.
19. Lopez EL, Contrini MM, Mistchenko A, et al. Long-Term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J. 2010;29:568-570.
20. Lopez EL, Del Carmen Xifro M, Torrado LE, et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J. 2001;20:48-52.
21. Miller WJ, Clark W, Hurni W, et al. Sensitive assays for hepatitis A antibodies. J Med Virol. 1993;41:201-204.
22. Stoof SP, Heijstek MW, Sijssens KM, et al. Kinetics of the long-Term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: A retrospective cohort study. Ann Rheum Dis. 2014;73:728-734.
23. Andraud M, Lejeune O, Musoro JZ, et al. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. PLoS Comput Biol. 2012;8:e1002418.
24. David MP, Van Herck K, Hardt K, et al. Long-Term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-Adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115(3 suppl):S1-S6.
25. Vereecken K, Naus CW, Polman K, et al. Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Trop Med Int Health. 2007;12:431-444.
26. Abe M, Okada K, Hayashida K, et al. Duration of neutralizing antibody titer after Japanese encephalitis vaccination. Microbiol Immunol. 2007;51:609-616.
27. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142:333-341.
28. Diggle P, Heagerty P, Liang K-Y, et al. Analysis of Longitudinal Data. Oxford Statistical Science Series. Oxford: Oxford University Press; 2009.
29. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. II ed. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2011.
30. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716-723.
31. Schwarz GE, Estimating the dimension of a model. Ann Statist. 1978;6:461-464.
32. Espul C, Benedetti L, Cuello H, et al. Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat Med. 2012;4:53-60.
33. Van Damme P, Leroux-Roels G, Crasta P, et al. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. J Med Virol. 2012;84:11-17.
34. World Health Organization. The Immunological Basis for Immunization Series: Module 18-Hepatitis A. Geneva: WHO; 2010. Available at:http://whqlibdoc. who.int/publications/2011/9789241501422-eng.pdf. Accessed August 13, 2013.
35. Hammitt LL, Bulkow L, Hennessy TW, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198:1776-1782.
36. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1-23.
37. Symbicort, S.P.C. Available at: http://www.medicines.org.uk/emc/medicine/11882/SPC/Symbicort+Turbohaler+400+12, +Inhalation+powder. Accessed June 11, 2014.
38. Flutivent, S.P.C. Available at: http://www.medicines.org.uk/emc/medicine/2317/ SPC/Seretide+100, +250, +500+Accuhaler. Accessed June 11, 2014.
39. Pigeon JG, Bohidar NR, Zhang Z, et al. Statistical models for predicting the duration of vaccine-induced protection. Drug Inf J. 1999;33:811-819.
40. Raczniak GA, Thomas TK, Bulkow LR, et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine. 2013;31:2152-2155.
41. Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 2005;23:5144-5148.
42. Cederna JB, Klinzman D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalininactivated hepatitis A vaccine. Vaccine. 1999;18:892-898.
43. Iwarson S, Lindh M, Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis. 2002;34:110-111.
44. Orr N, Klement E, Gillis D, et al. Long-Term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. Vaccine. 2006;24:4328-4332.
45. Van Herck K, Van Damme P, Lievens M, et al. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol. 2004;72:194-196.
46. Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine. 2003;21:3208-3211.